Juno Therapeutics' Lead Drug Trial Halted As Patients Die From Neurotoxicity

Bad news from the world of cancer immunotherapy. Seattle-based Juno Therapeutics is announcing today that its lead drug candidate has been put on clinical hold by the FDA after two patients died in a clinical trial from neurotoxicity-related complications.